Antares Pharma (ATRS) Tops Q2 EPS by 2c

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $10.93 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• MP Materials seen largely insulated after China export-control move